Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis announced the acquisition of Ducentis BioTherapeutics for approximately $30 million in cash and stock, targeting the development of DS-234, a promising treatment for atopic dermatitis. The growing market shows a significant unmet need, and DS-234 aims to be a best-in-class option, complementing Arcutis’ existing therapies. The acquisition leverages Arcutis’ dermatology expertise, with the goal of advancing innovative therapies to address critical patient needs in immune-mediated diseases.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the presentation of four abstracts for its topical roflumilast program at the EADV Congress from September 7-10, 2022. Key highlights include the oral presentation of data from the STRATUM Phase 3 trial of roflumilast foam in seborrheic dermatitis, scheduled for September 9. The company emphasizes the unmet need for non-steroidal treatments, showcasing the safety and efficacy of ZORYVE (roflumilast cream) for plaque psoriasis. This initiative underscores Arcutis' commitment to addressing dermatological conditions.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the grant of 96,500 restricted stock units and options for 212,500 shares to 39 new employees as part of its 2022 Inducement Plan. These awards, approved by the Compensation Committee, were granted on September 1, 2022. The restricted stock units vest over four years, while the stock options have a ten-year term with an exercise price of $26.87 per share. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract top talent amid Arcutis' focus on immuno-dermatology innovations.
Arcutis Biotherapeutics (Nasdaq: ARQT) has appointed Neha Krishnamohan to its Board of Directors, expanding the board to 10 members. Krishnamohan, previously involved in Arcutis' IPO, brings over 12 years of healthcare investment banking experience and currently serves as CFO of Kinnate Biopharma. Her expertise is expected to support Arcutis' growth following the recent commercialization of ZORYVE™ (roflumilast) cream for plaque psoriasis, a significant treatment for patients aged 12 and older. This strategic appointment aims to enhance the company's development pipeline and execution capabilities in dermatology.
Arcutis Biotherapeutics (Nasdaq: ARQT), focused on immuno-dermatology, announced participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 8:00 a.m. EDT. The event will feature a fireside chat with Arcutis management, providing insights into their innovative approach to treating immune-mediated dermatological conditions. A webcast of the conference will be available in the 'Events' section on the Arcutis website, with a replay accessible for 180 days post-event.
Arcutis Biotherapeutics (NASDAQ: ARQT) launched the Expose Psoriasis campaign during Psoriasis Action Month, focusing on the significant physical and emotional impact of plaque psoriasis. Aimed at empowering patients to communicate openly with healthcare providers, family, and friends, the campaign features expert dermatological advice and personal stories. It highlights the challenges of discussing psoriasis symptoms, particularly in sensitive areas, and the importance of addressing both physical and emotional well-being in treatment. The initiative also emphasizes the need for strong support networks for those affected.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the completion of enrollment for its INTEGUMENT-2 Phase 3 trial, evaluating roflumilast cream 0.15% for atopic dermatitis in individuals aged six and older. A total of 683 subjects were enrolled in this pivotal study, following the earlier completion of the INTEGUMENT-1 trial. Topline data from both trials is expected by the end of 2022, which could support a supplemental New Drug Application (sNDA) in 2023 if results are favorable. Atopic dermatitis affects approximately 26 million individuals in the U.S., highlighting a significant unmet medical need.
Arcutis Biotherapeutics has launched Arcutis Cares, the first patient assistance program for its topical psoriasis treatment, ZORYVE (roflumilast) cream 0.3%. This initiative offers ZORYVE at no cost to financially eligible individuals who are uninsured or underinsured. The program is open to those aged 12 and older residing in the U.S. and needing ZORYVE for FDA-approved uses. Additionally, a savings card for individuals with commercial insurance allows for reduced out-of-pocket costs. Arcutis aims to enhance accessibility and affordability of its treatment.
Arcutis Biotherapeutics has launched ZORYVE (roflumilast) cream 0.3%, the first topical PDE4 inhibitor for treating plaque psoriasis in patients aged 12 and older. This steroid-free cream rapidly clears plaques and alleviates itch, including in hard-to-treat areas. ZORYVE is available nationwide through pharmacies by prescription. The company emphasizes accessibility through responsible pricing and patient support programs, including Arcutis Cares™ for uninsured patients. FDA approval was granted on July 29, 2022, marking a significant milestone for Arcutis in immuno-dermatology.
Arcutis Biotherapeutics has received FDA approval for ZORYVE™ (roflumilast) cream 0.3%, a steroid-free treatment for plaque psoriasis in individuals aged 12 and older. The company also reported positive topline results from a pivotal Phase 3 trial for roflumilast foam aimed at seborrheic dermatitis, with an NDA submission expected in Q1 2023. Arcutis completed enrollment in the INTEGUMENT-1 trial for atopic dermatitis and bolstered its balance sheet with over $285 million from recent financings. As of June 30, 2022, the company had cash resources of approximately $570 million to support product launches and pipeline development.